PubRank

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Clinical Trial ID NCT00120848

PubWeight™ 28.86‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00120848

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 7.83
2 Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 5.68
3 Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009 1.75
4 Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009 1.49
5 Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014 1.48
6 Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG 2014 1.44
7 Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008 1.43
8 Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health 2014 0.90
9 Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother 2015 0.89
10 Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV. J Immunol Res 2015 0.84
11 Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother 2014 0.82
12 Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections. PLoS One 2013 0.80
13 E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS One 2012 0.79
14 Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol 2012 0.77
15 Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. J Infect Dis 2016 0.75
16 Response letter regarding the letter to the editors by Brown et al. Hum Vaccin Immunother 2016 0.75
17 Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. BMJ Open 2016 0.75
Next 100